Chemotherapy-treated mice had lower endocannabinoid levels in their paws, and restoring them relieved pain
Mice with chemotherapy-induced nerve pain had reduced levels of the endocannabinoid 2-AG specifically in their paw tissue, and local administration of 2-AG or a compound that prevents its breakdown relieved pain.
Quick Facts
What This Study Found
2-AG levels were significantly reduced in the paw skin but not in the brain or spinal cord of paclitaxel-treated mice. Injecting 2-AG or the MAGL inhibitor JZL184 directly into the paw reversed pain sensitivity, and this effect required both CB1 and CB2 receptors.
Key Numbers
2-AG levels were reduced only in paw skin, not in brain or spinal cord. Antiallodynic effects of 2-AG were blocked by both CB1 antagonist AM251 and CB2 antagonist AM630. Effects were limited to the injected paw only.
How They Did This
Female BALB/c mice received paclitaxel to induce mechanical allodynia. Endocannabinoid levels were measured in brain, spinal cord, and paw skin using LC-MS/MS. Local injection of 2-AG or MAGL inhibitor into the hind paw was tested for antiallodynic effects.
Why This Research Matters
Chemotherapy-induced neuropathic pain is a common and difficult-to-treat side effect. Finding that the endocannabinoid system is specifically depleted at the site of pain suggests targeted local treatments could help.
The Bigger Picture
This study suggests that chemotherapy-induced nerve pain may involve a peripheral endocannabinoid deficiency rather than a central nervous system problem, pointing toward localized rather than systemic cannabinoid treatments.
What This Study Doesn't Tell Us
Animal study using only female mice of one strain. Endocannabinoid measurements were taken at a single time point. Local injection is not a practical delivery method for clinical use.
Questions This Raises
- ?Do similar peripheral 2-AG deficits occur in humans with chemotherapy-induced neuropathy?
- ?Could topical cannabinoid or MAGL inhibitor formulations provide the same localized relief?
- ?Would results differ in male mice?
Trust & Context
- Key Stat:
- 2-AG depleted in paw skin but not in brain or spinal cord
- Evidence Grade:
- Well-designed preclinical study with clear mechanistic findings, but limited to a single mouse strain and sex.
- Study Age:
- 2020 animal study. Provides mechanistic basis for potential topical cannabinoid treatments for chemo-induced neuropathy.
- Original Title:
- Peripheral deficiency and antiallodynic effects of 2-arachidonoyl glycerol in a mouse model of paclitaxel-induced neuropathic pain.
- Published In:
- Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 129, 110456 (2020)
- Authors:
- Thomas, Amal, Okine, Bright N(2), Finn, David P(8), Masocha, Willias
- Database ID:
- RTHC-02878
Evidence Hierarchy
Tests effects in animals (usually mice or rats), not humans.
What do these levels mean? →Frequently Asked Questions
What is 2-AG?
2-arachidonoyl glycerol (2-AG) is one of the body's main endocannabinoids, natural compounds that activate cannabinoid receptors. It plays roles in pain regulation, inflammation, and other processes.
Why was the endocannabinoid deficiency only in the paw?
The researchers found 2-AG was depleted only in the paw skin where nerve damage occurred, not in the brain or spinal cord. This suggests the deficit is localized to the site of injury rather than being a whole-body change.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-02878APA
Thomas, Amal; Okine, Bright N; Finn, David P; Masocha, Willias. (2020). Peripheral deficiency and antiallodynic effects of 2-arachidonoyl glycerol in a mouse model of paclitaxel-induced neuropathic pain.. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 129, 110456. https://doi.org/10.1016/j.biopha.2020.110456
MLA
Thomas, Amal, et al. "Peripheral deficiency and antiallodynic effects of 2-arachidonoyl glycerol in a mouse model of paclitaxel-induced neuropathic pain.." Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2020. https://doi.org/10.1016/j.biopha.2020.110456
RethinkTHC
RethinkTHC Research Database. "Peripheral deficiency and antiallodynic effects of 2-arachid..." RTHC-02878. Retrieved from https://rethinkthc.com/research/thomas-2020-peripheral-deficiency-and-antiallodynic
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.